Arch Therapeutics, Inc.
ARTH
$0.1574
-$0.0426-21.30%
| Weiss Ratings | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.88 | |||
| Price History | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -13.52% | |||
| 30-Day Total Return | -32.27% | |||
| 60-Day Total Return | -7.52% | |||
| 90-Day Total Return | -26.28% | |||
| Year to Date Total Return | -21.30% | |||
| 1-Year Total Return | -89.36% | |||
| 2-Year Total Return | -95.00% | |||
| 3-Year Total Return | -99.09% | |||
| 5-Year Total Return | -99.63% | |||
| 52-Week High % Change | -87.24% | |||
| 52-Week Low % Change | 27.15% | |||
| Price | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.57 | |||
| 52-Week Low Price | $0.16 | |||
| 52-Week Low Price (Date) | Apr 10, 2025 | |||
| 52-Week High Price (Date) | May 21, 2024 | |||
| Valuation | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 888.87K | |||
| Enterprise Value | 10.25M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.62 | |||
| Earnings Per Share Growth | -48.54% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 6.01 | |||
| Price/Book (Q) | -0.07 | |||
| Enterprise Value/Revenue (TTM) | 69.14 | |||
| Price | $0.16 | |||
| Enterprise Value/EBITDA (TTM) | -2.17 | |||
| Enterprise Value/EBIT | -2.17 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 4.44M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 431 2313 | |||
| Address | 235 Walnut Street Framingham, MA 01702 | |||
| Website | www.archtherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2006 | |||
| Profitability | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -3,186.09% | |||
| Profit Margin | -8,274.42% | |||
| Management Effectiveness | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -199.28% | |||
| Return on Equity | -- | |||
| Income Statement | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 148.20K | |||
| Total Revenue (TTM) | 148.20K | |||
| Revenue Per Share | $0.03 | |||
| Gross Profit (TTM) | 58.60K | |||
| EBITDA (TTM) | -4.72M | |||
| EBIT (TTM) | -4.72M | |||
| Net Income (TTM) | -12.26M | |||
| Net Income Avl. to Common (TTM) | -12.26M | |||
| Total Revenue Growth (Q YOY) | 132.33% | |||
| Earnings Growth (Q YOY) | -210.17% | |||
| EPS Diluted (TTM) | -2.62 | |||
| EPS Diluted Growth (Q YOY) | -0.86% | |||
| Balance Sheet | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 30.00K | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 1.39M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -12.56M | |||
| Current Ratio (Q) | 0.100 | |||
| Book Value Per Share (Q) | -$2.83 | |||
| Total Assets (Q) | 1.40M | |||
| Total Current Liabilities (Q) | 13.96M | |||
| Total Debt (Q) | 9.39M | |||
| Total Liabilities (Q) | 13.96M | |||
| Total Common Equity (Q) | -12.56M | |||
| Cash Flow | ARTH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -4.50K | |||
| Cash from Financing (TTM) | 3.65M | |||
| Net Change in Cash (TTM) | -56.50K | |||
| Levered Free Cash Flow (TTM) | -3.73M | |||
| Cash from Operations (TTM) | -3.70M | |||
